Application 022292

Type
NDA
Sponsor
BOEHRINGER INGELHEIM

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001APTIVUSTIPRANAVIRSOLUTION;ORAL100MG/MLYesYes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N022292-001APTIVUSTIPRANAVIR100MG/MLSOLUTION / ORALRLD2008-06-23

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 2 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N022292-001APTIVUS100MG/MLSOLUTION / ORALRLD, RS2008-06-233a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N022292-001APTIVUS100MG/MLSOLUTION / ORALRLD, RS2008-06-23f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N022292-001APTIVUS100MG/MLSOLUTION / ORALRLD, RS2008-06-23e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N022292-001APTIVUS100MG/MLSOLUTION / ORALRLD, RS2008-06-23cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N022292-001APTIVUS100MG/MLSOLUTION / ORALRLD2008-06-23a50c72e98297…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2019-12-13 00:20 UTC2019-12N022292-00158521952019-06-22Drug substance74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N022292-00161470952019-10-29U-67074a2ff9319b5…
2019-12-13 00:20 UTC2019-12N022292-0015852195*PED2019-12-22Pediatric extension74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N022292-0016147095*PED2020-04-29Pediatric extension74a2ff9319b5…
2020-12-22 03:56 UTC2020-12N022292-0016147095*PED2020-04-29Pediatric extension8869cabd3fbd…
2020-11-12 02:37 UTC2020-11N022292-0016147095*PED2020-04-29Pediatric extensionc0c555d07b60…
2019-12-14 00:12 UTC2019-12N022292-00158521952019-06-22Drug substance3f01610625f2…
2019-12-14 00:12 UTC2019-12N022292-00161470952019-10-29U-6703f01610625f2…
2019-12-14 00:12 UTC2019-12N022292-0015852195*PED2019-12-22Pediatric extension3f01610625f2…
2019-12-14 00:12 UTC2019-12N022292-0016147095*PED2020-04-29Pediatric extension3f01610625f2…
2019-09-15 20:21 UTC2019-09N022292-00158521952019-06-22Drug substanceb00525d2431f…
2019-09-15 20:21 UTC2019-09N022292-00161470952019-10-29U-670b00525d2431f…
2019-09-15 20:21 UTC2019-09N022292-0015852195*PED2019-12-22Pediatric extensionb00525d2431f…
2019-09-15 20:21 UTC2019-09N022292-0016147095*PED2020-04-29Pediatric extensionb00525d2431f…
2019-07-19 19:46 UTC2019-07N022292-00158521952019-06-22Drug substanceea99ee380514…
2019-07-19 19:46 UTC2019-07N022292-00161470952019-10-29U-670ea99ee380514…
2019-07-19 19:46 UTC2019-07N022292-0015852195*PED2019-12-22Pediatric extensionea99ee380514…
2019-07-19 19:46 UTC2019-07N022292-0016147095*PED2020-04-29Pediatric extensionea99ee380514…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 4 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0597-0002AptivustipranavirBoehringer Ingelheim Pharmaceuticals, Inc.NDACurrent
0597-0002AptivustipranavirBoehringer Ingelheim Pharmaceuticals, Inc.NDACurrent
0597-0002AptivustipranavirBoehringer Ingelheim Pharmaceuticals, Inc.NDACurrent
0597-0002AptivustipranavirBoehringer Ingelheim Pharmaceuticals, Inc.NDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
63655SUPPL2020-06-22
63654SUPPL2020-06-22
63653SUPPL2020-06-22
63632SUPPL2020-06-19
54856SUPPL2018-07-06
54717SUPPL2018-06-28
45376SUPPL2016-09-23
45344SUPPL2016-09-20
38528SUPPL2015-04-07
29547SUPPL2015-04-01
38527SUPPL2014-04-08
29546SUPPL2014-04-08
29545SUPPL2012-02-27
17212SUPPL2012-02-22
29544SUPPL2011-04-07
38526SUPPL2011-04-06
7197SUPPL2010-09-07
38525SUPPL2010-08-16
44728ORIG2010-05-12
42481ORIG2010-05-12
17211SUPPL2010-05-07
7196SUPPL2010-05-03
38524SUPPL2009-06-24
7195SUPPL2009-06-24
17210ORIG2008-06-26
7194ORIG2008-06-26